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prevents obesity-induced type II to type I muscle
fiber transition and favors an oxidative
phenotype of skeletal muscle
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Background: In the present study, we tested the hypothesis that carnitine supplementation counteracts obesity-
induced muscle fiber transition from type I to type II.
Methods: 24 obese Zucker rats were randomly divided into two groups of 12 rats each (obese control, obese
carnitine) and 12 lean Zucker rats were selected for lean control group. A control diet was given to both control
groups and a carnitine supplemented diet (3 g/kg diet) was given to obese carnitine group for 4 wk. Components
of the muscle fiber transformation in skeletal muscle were examined.
Results: The plasma level of carnitine were lower in the obese control group compared to the lean control group
and higher in the obese carnitine group than in the other groups (P < 0.05). Plasma concentrations of triglycerides
and non-esterified fatty acids were increased in obese animals compared to lean animals and the obese carnitine
group had lower level compared to the obese control group (P < 0.05). The obese carnitine group had an increased
number of type I muscle fibers and higher mRNA levels of type I fiber-specific myosin heavy chain, regulators of
muscle fiber transition and of genes involved in carnitine uptake, fatty acid transport, β-oxidation, angiogenesis,
tricarboxylic acid cycle and thermo genesis in M. rectus femoris compared to the other groups (P < 0.05).
Conclusion: The results demonstrate that carnitine supplementation to obese Zucker a rat counteracts the obesity-
induced muscle fiber transition and restores the muscle oxidative metabolic phenotype. Carnitine supplementation
is supposed to be beneficial for the treatment of elevated levels of plasma lipids during obesity or diabetes.
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The different contractile and metabolic functions of in-
dividual skeletal muscles in the body are caused by a dif-
ferent muscle fiber distribution. Two major types of
muscle fibers, which differ in their myosin heavy-chain
(MHC) isoforms and their enzymatic capacity [1], can be
distinguished. Type I fibers are mitochondria-rich, have
a high oxidative capacity utilizing mostly oxidative phos-
phorylation [2,3], and are myoglobin-rich with red* Correspondence: klaus.eder@ernaehrung.uni-giessen.de
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reproduction in any medium, provided the orappearance. Type II fibers (subdivided in IIa, IIb and
IId/x) have a lower oxidative capacity due to fewer mito-
chondria content than type I muscle fibers and thus de-
pend on glycolytic metabolism to generate ATP.
Interestingly, muscle fiber distribution is altered by
genetic and/or high fat diet-induced obesity due to in-
duction of fiber transition from type I to type II thereby
leading to a change of the muscle’s metabolic phenotype
[4-7]. The resulting reduced type I fiber content is asso-
ciated with mitochondrial dysfunction characterized by
an impaired mitochondrial oxidative enzyme capacity of
skeletal muscle [8]. Noteworthy, genetic and/or high fat
diet-induced obesity and diabetes cause an impairment
of carnitine status [9-11], whereas normalization ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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verses mitochondrial dysfunction under these conditions
[4,9,10,12,13]. At large, these findings indicate that car-
nitine supplementation through normalizing carnitine
status is able to prevent type I to type II fiber transition
and thereby the metabolic shift from oxidative to glyco-
lytic of skeletal muscle under unloading conditions or
metabolic stress.
Obesity- and diabetes-induced type I to type II fiber
transition and decreases of oxidative capacity of skeletal
muscle has been explained by down-regulation of per-
oxisome proliferator-activated receptor γ, coactivator-1α
(PGC-1α) and peroxisome proliferator-activated receptor
δ (PPARδ) [4,9,14]. Both, PGC-1α and PPARδ are crit-
ical regulators of genes involved in type II to type I fiber
transition, mitochondrial biogenesis, cellular and mito-
chondrial fatty acid uptake, β-oxidation, carnitine up-
take, tricarboxylic acid cycle, respiratory chain, and
angiogenesis [15-20]. Due to these functions PPARδ and
PGC-1α are typically higher expressed in oxidative type
I muscle fibers than in glycolytic type II muscle fibers
[15,21]. Interestingly, carnitine supplementation was
reported to increase expression of PGC-1α and PPARδ
in rodent models of unloading [4], and genetic and diet-
induced obesity and diabetes [10]. Based on these obser-
vations we hypothesized that carnitine supplementation
through inducing PGC-1α and PPARδ in skeletal muscle
counteracts obesity and/or diabetes-induced muscle
fiber transition from type I to type II and restores the
muscle fiber distribution and the muscle oxidative meta-
bolic phenotype observed during non-obese and non-
diabetic states. As a model object we used obese Zucker
rats, an established genetic model of obesity, insulin re-
sistance, and metabolic syndrome, which were fed either
a carnitine supplemented or a control diet with a low
native carnitine concentration for 4 wk. Lean Zucker
rats served as healthy non-obese and non-diabetic
controls.
Methods
Animals and housing
24 male obese (fa/fa) Zucker rats (Crl:ZUC-Leprfa;
Charles River, France) were randomly divided in two
groups of 12 rats each. They had an initial body weight
of 357 ± 4 (mean ± SEM) g and aged 8–10 weeks. In
addition, 12 male heterozygous lean (fa/+) Zucker rats
were used for the lean control group. They were also 8–
10 weeks old and had an initial body weight of 271 ± 3
(mean ± SEM) g. The rats were kept in Macrolon cages
in a controlled environment with a 12-h light–dark
cycle. All experimental procedures followed established
guidelines for the care and handling of laboratory ani-
mals and were approved by the local Animal Care and
Use Committee.Diets and feeding
The rats received two different semi-purified diets which
were composed according to the recommendations of
the American Institute of Nutrition (AIN)-93G [22]. The
first diet, which contained no carnitine supplement and
had a very low carnitine concentration of below < 5 mg
carnitine/kg diet, was given to the lean control and the
obese control group. The second diet containing 3 g car-
nitine/kg diet was given to the obese carnitine group.
Both diets contained (g/kg diet): corn starch, 530; casein,
200; saccharose, 100; soybean oil, 70; cellulose, 50; min-
erals, 30; vitamins, 20. Carnitine was added to the obese
carnitine diet at the expense of corn starch. The diets
were prepared by mixing the dry components and subse-
quent pelleting using a standard pelleting device (Kahl
Laborpressanlage Typ 14–175; Reinbek, Germany). Feed
and water was available ad libitum and feed intake was
recorded every week during the 28 days of the
experiment.
Sample collection
The rats of all groups were decapitated under CO2
anesthesia. Blood samples were taken into EDTA poly-
ethylene tubes (Sarstedt, Nürnbrecht, Germany) and
plasma was collected by centrifugation (1,100 × g;
10 min, 4°C). M. rectus femoris was excised, immediately
snap-frozen with liquid nitrogen and stored at −80°C
pending analysis.
Muscle fiber typing
For muscle fiber typing serial cross-sections of 30 μm
thickness from M. rectus femoris were prepared using a
cryostat microtome at −25°C and muscle fibers were
identified by their different inactivation of myofibrillar
actomyosin ATPase during acid preincubation, using a
modified method according to Hämäläinen and Pette
[23], as recently described [24].
Determination of plasma lipids
The concentration of triglycerides in plasma was deter-
mined using enzymatic reagent kits (refs. 157609990314
and 113009990314) [25]. Concentration of non-esterified
fatty acids (NEFA) in plasma was measured using the
NEFA kit from Wako Chemicals (ref. RD291001200R).
Determination of carnitine levels in plasma and muscle
Tandem mass spectrometry was used for determining the
concentrations of free carnitine and acetyl carnitine in
plasma and muscle. Total carnitine was calculated as the
sum of free carnitine and acetyl-carnitine. Deuterated
carnitine-d3 (Cambridge Isotype Laboratories, Andover,
MA, USA) was used as internal standard, according the
method of Hirche et al. [26].
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Total RNA was isolated from 20 mg skeletal muscle tis-
sue using Trizol™ reagent (Invitrogen, Karlsruhe,
Germany) according to the manufacturer’s protocol. Iso-
lated RNA was stored at −80°C. RNA concentration and
purity were estimated from the optical density at 260
and 280 nm (Infinite 200 M micro plate reader, Tecan,
Männedorf, Switzerland). The integrity of the RNA was
also verified by 1% agarose gel electrophoresis, which
showed intact bands corresponding to the 18S and 28S
ribosomal RNA subunits. cDNA synthesis and qPCR
analysis were performed as described recently in detail
[27]. Features of gene-specific primer pairs are listed in
Table 1. Calculation of gene expression data and
normalization by GeNorm normalization factor were
carried out as described recently [27]. In this study the
three most stable out of six tested potential reference
genes were CANX, TOP1 and YWHAZ in M. rectus
femoris (Table 2). Means and SEM were calculated from
normalized expression data for samples of the same
treatment group. The mean of the control obese group
was set to 1 and means and SEM of the other treatment
groups were scaled proportionally. Data on qPCR per-
formance for each gene measured in skeletal muscle are
shown in Table 1.
Western blotting
Homogenates were prepared and protein concentration
was determined as described recently [11]. After protein
separation by 12.5% SDS-PAGE the proteins were trans-
ferred to a nitrocellulose membrane and incubated with
primary antibodies against PGC-1α (polyclonal anti-
PGC-1α antibody; Millipore, Temecula, CA) and novel
organic cation transporter 2 (OCTN2) (polyclonal anti-
OCTN2 antibody; Lifespan Bioscience, Inc., Seattle, US)
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(monoclonal anti-GAPDH antibody, Abcam, Cambridge,
UK) as a reference protein. The membranes were washed,
and then incubated with a horseradish peroxidase conju-
gated secondary monoclonal anti-mouse-IgG antibody
(Sigma-Aldrich, Steinheim, Germany) for GAPDH and
polyclonal anti-rabbit-IgG antibody (DakoCytomation,
Glostrup, Denmark) for PGC-1α and OCTN2 at room
temperature. Afterwards blots were developed by ECL
Select (GE Healthcare, Munich, Germany) and the inten-
sities of the specific bands were detected with a Bio-
Imaging system (Syngene, Cambridge, UK) and quantified
by Syngene Gene Tools software (nonlinear dynamics).
Statistics
Statistical analysis of all data was done by one-way
ANOVA using the Minitab Statistical Software (Rel.
13.0, State College, PA, USA). Means of the three groups
were compared by Fisher’s multiple range tests. Meanswere considered significantly different for P < 0.05. Data
presented are shown as means ± SEM.
Results
Feed intake and body weight development
Initial and final body weights as well as daily body
weight gain were greater in the obese control group and
the obese carnitine group than in the lean control group
(P < 0.05; Table 3). Similarly, feed intake was greater in
the obese control group and the obese carnitine group
than in the lean control group (P < 0.05; Table 3). The
feed conversion ratio which describes gram feed per
gram body weight gain was increased significantly in the
lean control group (P < 0.05; Table 3). These parameters
did not differ between the two obese groups.
Concentration of carnitine in plasma and M. rectus
femoris
In line with recent observations, the obese control group
had lower concentrations of free carnitine, acetyl-
carnitine and total carnitine (= sum of free carnitine and
acetyl-carnitine) in plasma and rectus femoris muscle
than the lean control group (P < 0.05; Table 4). Due to
carnitine supplementation concentrations of free carni-
tine, acetyl-carnitine and total carnitine in plasma and
rectus femoris muscle were greater in the obese carni-
tine group than in the lean control group (P < 0.05;
Table 4).
Lipid concentrations in plasma and liver
As expected, rats of the obese groups had greater levels
of TG and NEFA in plasma and TG in the liver than
those of the lean group (P < 0.05; Table 4). Due to carni-
tine supplementation, however, concentrations of TG
and NEFA in plasma and TG in the liver were approxi-
mately 25–30% lower in the obese carnitine group than
in the obese control group (P < 0.05; Table 4).
Fiber type composition and expression of myosin heavy
chain isoforms in M. rectus femoris
Muscle fiber typing revealed an approximately 18% lower
percentage of type I muscle fibers in rectus femoris
muscle in the obese control group than in the lean control
group. Interestingly, the type I muscle fiber percentage in
rectus femoris muscle did not differ between the obese
carnitine group and the lean control group indicating that
carnitine supplementation prevented obesity-induced type
I to type II fiber transition (P < 0.05; Figure 1A, B). In con-
trast, the type II fiber percentage in rectus femoris muscle
was greater in the obese control group than in the other
two groups (P < 0.05; Figure 1A, B), but it did not differ
between the obese control group and the lean control
group. The composition of muscle fiber types in rectus
femoris muscle did not differ between the lean control
Table 1 Characteristics of primers used for qPCR
Gene symbol Primer sequence
(forward, reverse; from 5′ to 3′)
NCBI
GeneBank
Product
size (bp)
Slope R2# Efficiency*
(HUGO)
ACADL AAGGATTTATTAAGGGCAAGAAGC NM_012819 380 bp −3.88 0.998 1.81
GGAAGCGGAGGCGGAGTC
ACADM CAAGAGAGCCTGGGAACTTG NM_016986 154 bp −3.38 0.999 1.98
CCCCAAAGAATTTGCTTCAA
ATP5B GCACCGTCAGAACTATTGCT NM_134364 203 bp −3.59 0.999 1.90
GAATTCAGGAGCCTCAGCAT
CANX CCAGATGCAGATCTGAAGAC NM_172008 175 bp −2.75 0.999 2.31
CTGGGTCCTCAATTTCACGT
CD36 TCGTATGGTGTGCTGGACAT NM_031561 358 bp −3.28 0.996 2.02
GGCCCAGGAGCTTTATTTTC
CPT1B GCAAACTGGACCGAGAAGAG NM_013200 180 bp −3.32 0.988 2.00
CCTTGAAGAAGCGACCTTTG
FABP3 ACCATCCACTGCCGTCTTAC NM_013177 310 bp −3.20 0.957 2.05
CCCCGATGCGTAGGTATTCT
HK2 GATGGAATCGAGAAGGCCTA, NM_012735 220 bp −3.63 1.000 1.89
GTTTCTTGTAGACGGAGCCA
LPL GAGATTTCTCTGTATGGCACA NM_012598 276 bp −3.34 0.992 1.99
CTGCAGATGAGAAACTTTCTC
MDH1 CAGACAAAGAAGAGGTTGCC, NM_033235 206 bp −3.40 0.994 1.97
CGTCAGGCAGTTTGTATTGG
MYH1 GCAGACTCTCCCACTGGGCTG NM_001135158 83 bp −3.16 0.953 2.07
GAGCAGCCTCCCCGAAAACGG
MYH2 GCTGATCGAAATGCTGCTGA NM_001135157 124 bp −3.38 0.990 1.98
GTCAATAGCACTATCCGTGG
MYH4 CCAGTCCATCCTGATTACTG NM_019325 74 bp −3.48 0.988 1.94
CAAAGTACTGGATGACACGC
MYH7 ATTGCCGAGTCCCAGGTCAACA NM_017240 127 bp −3.24 0.944 2.03
GCTCCAGGTCTCAGGGCTTCAC
PFKM TCCTGGTTGGCTCAATCGAC NM_031715 297 bp −3.75 0.998 1.85
TGTTGAGACGAGAACCACGG
PKM ACCTGGGCATTGAGATTCCG NM_053297 314 bp −3.69 0.997 1.87
TCGCGCAAGCTCTTCAAACA
PPARD GCAGAGCTATGACCAGGCCTGCA NM_013141 151 bp −3.29 0.990 2.01
GTGCTCTGGTCCCCCGTTGA
PPARGC1A CTCTTTGCCCAGATCTTCCT NM_031347 145 bp −3.93 0.999 1.80
ATGTTCGCGGGCTCATTGTT
PPARGC1B CATATAAGCCCATGGAGGAG NM_176075 476 bp −3.25 0.978 2.03
CAGCCCAAAGTGCTTTGTGA
RPL13 CTTAAATTGGCCACGCAGCT XR_086310 198 bp −3.48 0.998 1.94
CTTCTCAACGTCTTGCTCTG
SDHA TGGACCTTGTCGTCTTTGG NM_130428 88 bp −3.90 0.997 1.80
TTTGCCTTAATCGGAGGAAC
SLC2A4 GAGTTATGTGTCCATCGTGG NM_012751 187 bp −2.59 0.953 2.40
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Table 1 Characteristics of primers used for qPCR (Continued)
CGCAACATACTGGAAACCCA
SLC22A5 GAACTCACGAGCCTCGCACGC NM_019269 117 bp −3.75 0.997 1.85
TCGTCGTAGTCCCGCATGCC
SLC25A20 AGCCCACCTGTTATCCACTG NM_053965 178 bp −3.32 0.988 2.00
TGTGCAAAAAGAGCCTTCCT
SLC27A1 GTATCTGCTGGACCTTCGC NM_053580 243 bp −3.48 0.990 1.94
CATAAATGAGGGCCTTGGCA
TOP1 GAAGAACGCTATCCAGAAGG NM_022615 137 bp −3.33 0.997 2.00
GCTTTGGGACTCAGCTTCAT
UCP1 CAGGCTTCCAGTACTATTAGG NM_012682 181 bp −3.40 0.983 1.97
CTCTCCCTGAAGAGAAGTACT
UCP2 CAAGGAGAGAGTCAAGGGCTA NM_019354 209 bp −3.08 0.998 2.11
GACTCTGAGCCCTTGGTGTAG
UCP3 CTCGGTACCATCCTGACTAT NM_013167 149 bp −3.47 0.982 1.94
GTTCCTTTGGGGGTGTAGAA
VEGFA GTTCATGGACGTCTACCAGC NM_031836 253 bp −3.62 0.973 1.89
GCTATGCTGCAGGAAGCTCA
VEGFB GTGTCCCAGTTTGATGGCC NM_053549 187 bp −3.45 1.000 1.95
CGTCAGGACAGCAGCCAC
YWHAZ GACGGAAGGTGCTGAGAAA NM_013011 198 bp −3.13 0.986 2.09
GCAGCAACCTCAGCCAAGT
#Coefficient of determination of the standard curve.
*The efficiency is determined by [10(−1/-slope].
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genes encoding the different myosin heavy-chain II
isoforms (MHCIIa encoded by MYH2, MHCIIb encoded
by MYH4, MHCIIx encoded by MYH1) did not differ be-
tween the groups (Figure 1C). However, the relative
mRNA level of MHCIb (encoded by MYH7), which en-
codes the type I fiber specific myosin heavy chain isoform;
in rectus femoris muscle was greater in the lean control
and the obese carnitine group than the obese control
group (P < 0.05; Figure 1B).Table 2 Average expression stability ranking of six
candidate reference genes
Ranking Gene M value
Most stable YWHAZ 0.056
TOP1 0.060
CANX 0.060
MDH1 0.062
ATP5B 0.073
Least stable RPL13 0.074
Ranking of the candidate reference genes according to their stability score M
as calculated by the Microsoft Excel-based application GeNorm.Expression of genes involved in muscle fiber
transformation in M. rectus femoris
The mRNA levels of the main regulators of muscle fiber
transformation PPARδ (encoded by PPARD), PGC-1α
(encoded by PPARGC1A) and PGC-1β (encoded by
PPARGC1B) in rectus femoris muscle were greater in the
obese carnitine than in obese control group (P < 0.05;
Table 5). The lean control and the obese control group
did not differ with regard to these genes.
The relative protein level of PGC-1α in rectus
femoris muscle was also greater in the obese carnitine
group than in the obese control and the lean control
group (P < 0.05; Figure 2). The relative protein level of
PPARδ in rectus femoris muscle was 33% higher in the
obese carnitine group than in the obese control group
but this effect was not significant (Figure 2).
Expression of genes involved in carnitine uptake, fatty
acid transport, fatty acid utilization, and glycolysis in M.
rectus femoris
The mRNA levels of genes involved in carnitine uptake
[SLC22A5 encoding organic cation/carnitine transporter
(OCTN2)], fatty acid transport and uptake (FABP3 en-
coding fatty acid binding protein 3, CD36 encoding fatty
acid translocase/CD36, LPL encoding lipoprotein lipase),
Table 3 Feed intake and body weight gains of lean rats (lean control), obese Zucker rats fed a control diet (obese
control) or obese Zucker rats fed a diet supplemented with 3 g/kg diet carnitine (obese carnitine) for 4 wk1
Lean Obese Obese
control control carnitine
Feed intake (g/d) 19.7 ± 0.2c 25.2 ± 0.5b 26.4 ± 0.4a
Initial body weight (g) 271 ± 3b 357 ± 6a 358 ± 7a
Final body weight (g) 367 ± 4b 501 ± 7a 496 ± 9a
Daily body weight gain (g) 3.35 ± 0.08b 5.03 ± 0.13a 4.85 ± 0.14a
Feed conversion ratio (g feed/g body weight) 5.90 ± 0.11a 5.02 ± 0.09b 5.18 ± 0.18b
1Data are expressed as means ± SEM, n = 12 rats/group. Means in a row without a common letter differ (P < 0.05).
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CoA dehydrogenase and medium chain acyl-CoA de-
hydrogenase, respectively), carnitine shuttle (SLC25A20
encoding carnitine/acylcarnitine translocase), and glycoly-
sis (HK2 encoding hexokinase 2) in rectus femoris muscle
were greater in the obese carnitine group than in the
obese control group (P < 0.05; Table 5). The mRNA
levels of SLC27A1 encoding fatty acid transport protein,
CPT1B (encoding carnitine-palmitoyl transferase 1b),
SLC2A4 encoding glucose transporter-4, PKM (pyruvate
kinase, muscle), and PFKM (encoding phosphofructoki-
nase, muscle) in rectus femoris muscle were numerically
greater in the obese carnitine group than in the obese
control group, but the differences were not significant
(Table 5).Table 4 Plasma and muscle (M. rectus femoris)
concentrations of carnitine, plasma concentrations of TG
and NEFA and liver concentration of TG in lean rats (lean
control), obese Zucker rats fed a control diet (obese
control) or obese Zucker rats fed a diet supplemented
with 3 g/kg diet carnitine (obese carnitine) for 4 wk1
Lean Obese Obese
control control carnitine
Plasma (μmol/l)
Total carnitine 62.3 ± 1.9b 40.0 ± 1.1c 90.5 ± 2.9a
Free carnitine 50.8 ± 1.6b 33.7 ± 1.2c 73.2 ± 2.5a
Acetyl-carnitine 11.5 ± 0.9b 6.3 ± 0.3c 17.3 ± 0.8a
M. rectus femoris (nmol/g)
Total carnitine 919 ± 13b 752 ± 13c 1165 ± 19a
Free carnitine 742 ± 12b 590 ± 9c 937 ± 21a
Acetyl-carnitine 176 ± 4b 161 ± 4b 228 ± 6a
Plasma (mmol/l)
TG 1.42 ± 0.06c 6.35 ± 0.18a 4.42 ± 0.26b
NEFA 0.73 ± 0.06c 3.53 ± 0.16a 2.41 ± 0.18b
Liver (μmol/g)
TG 10.2 ± 0.9b 87.7 ± 13.7a 65.6 ± 8.1a
1Data are expressed as means ± SEM, n = 12 rats/group. Means in a row
without a common letter differ (P < 0.05).The relative protein level of OCTN2 in rectus femoris
muscle was also greater in the obese carnitine group
than in the other groups (P < 0.05; Figure 3).
Expression of genes involved in angiogenesis,
tricarboxylic acid cycle and mitochondrial respiratory
chain and thermo genesis in M. rectus femoris
Relative mRNA levels of genes encoding vascular endo-
thelial growth factor b (VEGFB), succinate dehydrogen-
ase subunit A (SDHA) and uncoupling proteins (UCP1
and UCP2) in rectus femoris muscle were greater in the
obese carnitine group than in the obese control and the
lean control group (P < 0.05; Table 6). The mRNA level
of UCP3 in rectus femoris muscle was numerically
greater in the obese carnitine group than in the obese
control and lean control group, but this effect was not
significant (Table 6).
Discussion
In the present study we tested the hypothesis that carni-
tine supplementation to obese Zucker rats counteracts
the obesity-induced muscle fiber transition from type I
to type II and, thereby, improves fatty acid utilization in
skeletal muscle. The dietary carnitine dosage (3 g/kg
diet) fed to the rats related to 156 to 216 mg/kg body
weight based on an average daily feed consumption of
26 g and a body weight of 360 (initial) to 500 (final) g.
This carnitine dosage is slightly higher when compared
to that used in clinical studies with human subjects with
different metabolic disorders in which carnitine dosages
of up to 4 g/d corresponding to 60 mg/kg body weight
for an individual weighing 70 kg were found to be effect-
ive [28]. A key finding of the present study is that
carnitine supplementation to obese rats resulted in an
increased number of type I fibers and a decreased num-
ber of type II fibers in rectus femoris muscle when com-
pared to non-supplemented obese rats. This indicates
that carnitine induces type II to type I fiber transition in
femoris muscle of obese rats which was also confirmed
by the finding that the type I fiber specific MYH7
mRNA level in rectus femoris muscle was markedly ele-
vated in the obese carnitine group. Interestingly, the
AB
C
Figure 1 Fiber distribution of M. rectus femoris of lean rats (lean control), Zucker rats fed a control diet (obese control) or Zucker rats
fed a diet supplemented with 3 g/kg diet carnitine (obese carnitine) for 4 wk. (A) muscle fiber type composition, (B) fiber type-specific
cross-sectional area, (C) relative mRNA expression of myosine heavy chain isoforms. Bars represent means ± SEM, n = 12 rats/group. Means
without a common letter differ (P < 0.05).
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similar between the obese carnitine and the lean control
group, whereas rectus femoris muscle of the obese con-
trol group had a lower number of type I fibers and a
greater number of type II fibers compared to that of the
lean control group. A reduction of type I fibers and a
lower oxidative enzyme activity in muscle of obese and
diabetic rodent models compared to lean models has
been well documented [6,7]. In addition, several studies
reported that obese subjects have a decreased proportion
of type I muscle fibers and an overall decrease in mito-
chondrial enzymes indicating that muscle oxidative cap-
acity is impaired in obese subjects [29-32], which likelycontributes to the impaired whole body fatty acid
utilization and the elevated blood lipid levels in these
subjects. Moreover, it was shown that insulin sensitivity
correlates positively with the proportion of type I muscle
fibers and negatively with the proportion of type II
muscle fibers [29-31]. There is a large body of evidence
that carnitine supplementation improves glucose tolerance
in insulin resistant and/or diabetic humans (reviewed by
[28]). The observed up-regulation of genes in involved in
glycolysis (HK2) by carnitine in muscle of the obese
rats is also supportive of a beneficial effect of carnitine
on glucose homeostasis. Insulin resistant and/or diabetic
subjects are likely particularly sensitive to carnitine
Table 5 Relative mRNA levels of genes involved in
carnitine uptake, fatty acid transport, fatty acid
utilization, and glucose uptake and glycolysis in M. rectus
femoris of lean rats (lean control), obese Zucker rats fed a
control diet (obese control) or obese Zucker rats fed a
diet supplemented with 3 g/kg diet carnitine (obese
carnitine) for 4 wk1
Lean Obese Obese
control control carnitine
Fold of obese control
Muscle fiber transformation
PPARD 1.11 ± 0.19b 1.00 ± 0.12b 4.18 ± 0.58a
PPARGC1A 1.21 ± 0.17b 1.00 ± 0.16b 2.14 ± 0.42a
PPARGC1B 0.78 ± 0.06b 1.00 ± 0.24b 2.02 ± 0.24a
Carnitine uptake
SLC22A5 0.92 ± 0.12b 1.00 ± 0.08b 1.90 ± 0.25a
Fatty acid transport and uptake
FABP3 1.05 ± 0.28b 1.00 ± 0.34b 2.18 ± 0.46a
SLC27A1 1.19 ± 0.34 1.00 ± 0.23 1.46 ± 0.30
CD36 0.71 ± 0.14b 1.00 ± 0.11b 1.52 ± 0.20a
LPL 1.14 ± 0.22b 1.00 ± 0.28b 2.22 ± 0.35a
β-oxidation
ACADM 1.79 ± 0.44b 1.00 ± 0.20b 3.39 ± 0.86a
ACADL 1.11 ± 0.23b 1.00 ± 0.24b 2.25 ± 0.61a
Carnitine shuttle
CPT1B 1.25 ± 0.31 1.00 ± 0.35 1.49 ± 0.27
SLC25A20 1.46 ± 0.14a 1.00 ± 0.07b 1.39 ± 0.13a
Glucose uptake and glycolysis
SLC2A4 1.41 ± 0.34 1.00 ± 0.32 1.52 ± 0.18
HK2 1.32 ± 0.37b 1.00 ± 0.51b 3.11 ± 0.18a
PKM 1.87 ± 0.94 1.00 ± 0.33 2.36 ± 0.46
PFKM 1.20 ± 0.51 1.00 ± 0.32 1.23 ± 0.25
1Data are expressed as means ± SEM, n = 12 rats/group. Means and SEM of
the other groups were presented as fold of the obese control group, which
mean was set to 1. Means in a row without a common letter differ (P < 0.05).
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Figure 2 Relative protein level of PGC-1α (A) and PPARδ (B) in
M. rectus femoris of lean rats (lean control), Zucker rats fed a
control diet (obese control) or Zucker rats fed a diet
supplemented with 3 g/kg diet carnitine (obese carnitine) for 4
wk. Bars represent means ± SEM, n = 6/group. Means without a
common letter differ (P < 0.05). (C) Representative immunoblots
specific to PGC-1α, PPARδ and GAPDH as internal control are shown
for one animal per group; immunoblots for the other animals
revealed similar results.
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http://www.nutritionandmetabolism.com/content/10/1/48supplementation because diabetic subjects were reported
to have diminished plasma free carnitine concentrations,
even though the levels were still within or only slightly
below the physiological range (25–50 μmol/l) reported for
healthy subjects [33-35]. Given the observed increase in
type I muscle fiber proportion in obese rats and the rela-
tionship between type I muscle fiber proportion and in-
sulin sensitivity it is not unlikely that the improvement
of glucose tolerance and insulin sensitivity by carnitine
supplementation in obese and diabetic subjects is due
to the effect of carnitine on muscle fiber distribution.
Even though a very recent study reported that carnitine
supplementation at a non-physiologically high dosage
promoted intestinal formation of the proatherogenictrimethylamine-N-oxide and accelerated atherosclerosis
development in mice [36], the fact that none of the carni-
tine supplementation studies in humans reported any ad-
verse effects even at very high dosages (e.g., 4 g oral
carnitine) indicates that safety concerns with carnitine
supplementation are unfounded. Collectively, the present
findings corroborate our hypothesis that carnitine supple-
mentation to obese rats counteracts the obesity-induced
AB
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Figure 3 Relative protein level of OCTN2 in M. rectus femoris of
lean rats (lean control), Zucker rats fed a control diet (obese
control) or Zucker rats fed a diet supplemented with 3 g/kg
diet carnitine (obese carnitine) for 4 wk. (A) Bars represent
means ± SEM, n = 6/group. Means without a common letter differ
(P < 0.05). (B) Representative immunoblots specific to OCTN2 and
GAPDH as internal control are shown for one animal per group;
immunoblots for the other animals revealed similar results.
Table 6 Relative mRNA levels of genes involved in
angiogenesis, mitochondrial respiratory chain and
uncoupling proteins in M. rectus femoris of lean rats
(lean control), obese Zucker rats fed a control diet (obese
control) or obese Zucker rats fed a diet supplemented
with 3 g/kg diet carnitine (obese carnitine) for 4 wk1
Lean Obese Obese
control control carnitine
Fold of obese control
Angiogenesis
VEGFA 0.81 ± 0.18 1.00 ± 0.30 1.30 ± 0.37
VEGFB 1.62 ± 0.35ab 1.00 ± 0.19b 2.21 ± 0.28a
TCA cycle and respiratory chain
SDHA 1.26 ± 0,25ab 1.00 ± 0.24b 2.18 ± 0.40a
Thermogenesis
UCP1 1.67 ± 0.35b 1.00 ± 0.12b 7.06 ± 1.27a
UCP2 1.07 ± 0.23b 1.00 ± 0.24b 3.39 ± 0.34a
UCP3 0.97 ± 0.20 1.00 ± 0.25 1.92 ± 0.70
1Data are expressed as means ± SEM, n = 12 rats/group. Means and SEM of
the other groups were presented as fold of the obese control group, which
mean was set to 1. Means in a row without a common letter differ (P < 0.05).
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http://www.nutritionandmetabolism.com/content/10/1/48muscle fiber transition from type I to type II and is able to
restore the muscle fiber distribution and the oxidative
metabolic phenotype observed in lean animals.
This study showed that carnitine supplementation in
obese rodents resulted in a higher type I muscle fiber
content compared to obese rats without carnitine sup-
plementation. The observed decrease of carnitine levels
in plasma and muscle in the obese control group is con-
sistent with observations from recent studies showing that
whole body carnitine status is strongly compromised in
rodent models of genetic and diet-induced obesity and
diabetes [10]. As the main reason for this phenomenon an
impaired hepatic carnitine biosynthesis has been identified
[10,11]. In contrast, carnitine supplementation to obese
and/or diabetic rodent models is able to restore the carni-
tine status to normal [10] or even supraphysiological levels
as shown herein. Although our observations do not proof
a causal link between carnitine status and muscle fiber
distribution, our results suggest that the carnitine-induced
change in muscle fiber distribution is due to an improve-
ment of carnitine status.
In addition, the present study shows that the carnitine-
induced change in the contractile phenotype of skeletal
muscle of obese rats is also accompanied by a change in
the metabolic phenotype. In agreement with the high con-
tent of mitochondria and the preferential use of fatty acids
for energy production of type I fibers, genes involved
in fatty acid transport and uptake (FABP3, CD36,
LPL), β-oxidation (ACADL, ACADM), carnitine shuttle
(SLC25A20), carnitine uptake (SLC22A5) and TCA cycle
and respiratory chain (SDHA) in femoris muscle were
strongly up-regulated in the obese carnitine compared to
the obese control group. In line with our findings in skel-
etal muscle, carnitine supplementation was also shown to
stimulate TCA activity, mitochondrial respiration and
ATP production in the diabetic rat heart [37,38]. Thus,
these carnitine-induced effects on gene expression of rec-
tus femoris muscle are indicative of an improved capacity
of the muscle for oxidative utilization of fatty acids. Since
skeletal muscle significantly contributes to whole-body
fatty acid utilization, the improved oxidative metabolic
phenotype of skeletal muscle at least partially explains
the pronounced NEFA- and TG-lowering effects of car-
nitine supplementation observed in the present rat
model of obesity and insulin resistance but also in other
studies [39].
To gain insight into the mechanisms underlying
muscle fiber transition we determined the mRNA and/
or protein levels of the main regulators of fiber compos-
ition. The two main regulators of type II to type I fiber
transition, mitochondrial biogenesis, and oxidative en-
zyme expression, PPARδ and PGC-1α, but also PGC-1β,
which induces similar effects as PGC-1α on the con-
tractile and metabolic phenotype of skeletal muscle
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http://www.nutritionandmetabolism.com/content/10/1/48[40,41], were clearly stronger expressed in rectus femoris
muscle of the obese carnitine group than in the obese
control group. Regarding that PGC-1α and PGC-1β also
regulate angiogenesis through inducing the expression of
angiogenic factors like VEGFs, we also determined tran-
script levels of VEGFA (encoding VEGFa) and VEGFB (en-
coding VEGFb). VEGFb particularly favors the utilization
of fatty acids not only by increasing capillary density and
thereby blood perfusion but also by inducing the expres-
sion of fatty acid transport proteins (FATPs, CD36) [42].
Correspondingly, VEGFb is mainly expressed in tissues
with high mitochondria content and with preferential use
of fatty acids as energy source like oxidative skeletal
muscle, heart, and brown adipose tissue [43]. The observa-
tion that the relative mRNA level of VEGFB was markedly
elevated in the obese carnitine group is therefore in line
with the induction of PGC-1α and PGC-1β and provides a
further indication for the improved oxidative phenotype of
rectus femoris muscle in rats of the obese carnitine group.
Collectively, our findings strongly suggest that the up-
regulation of genes encoding PGC-1α, PGC-1β, and
PPARδ in rectus femoris muscle by L-carnitine supplemen-
tation is responsible for the observed type II to type I fiber
transition and the oxidative metabolic phenotype of skel-
etal muscle of obese Zucker rats.
In conclusion, the results of this study demonstrate
that carnitine supplementation to obese Zucker rats sig-
nificantly improves carnitine status, counteracts the
obesity-induced muscle fiber transition from type I to
type II and favors an oxidative metabolic phenotype of
skeletal muscle which preferentially uses fatty acids as
energy source. The enhanced capacity of skeletal muscle
to utilize fatty acids was demonstrated by the carnitine-
induced up-regulation of genes involved in fatty acid
uptake and transport, carnitine uptake, fatty acid β-
oxidation, mitochondrial fatty acid uptake (carnitine
shuttle system) and tricarboxylic acid cycle. These meta-
bolic changes in skeletal muscle are likely to contribute
to the pronounced NEFA- and TG-lowering effects of
carnitine supplementation in obese Zucker rats. There-
fore, carnitine supplementation is supposed to be benefi-
cial for the treatment of elevated levels of metabolic
fuels (e.g., fatty acids) which are frequently found in sub-
jects with obesity, insulin resistance, diabetes or meta-
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